Viatris and Biocon have launched their Abevmy (bevacizumab) biosimilar rival to Avastin in Canada, representing the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in the market. The product is available in 100mg/4ml and 400mg/16ml single-use vials.
Ogivri (trastuzumab), Canada’s first Herceptin biosimilar to be approved, was launched in 2019, while Fulphila (pegfilgrastim) followed in 2020. Then...






